Literature DB >> 17132225

Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes.

Julia Diegmann1, Kerstin Junker, Ivan F Loncarevic, Susanne Michel, Bettina Schimmel, Ferdinand von Eggeling.   

Abstract

Tumors can escape immune recognition and destruction through the induction of apoptosis in lymphocytes. Although renal cell carcinoma (RCC) is able to prevent immune recognition, only a few genes (such as FasL) that are relevant for RCC immune escape have been identified so far. We have previously shown that some apoptosis-inducing genes are overexpressed in RCC. We hypothesized that these genes could be part of the immune-escape strategy of these tumors. Here we report that CD70, a cytokine overexpressed in RCC, promotes lymphocyte apoptosis through interaction with its receptor CD27 and with the intracellular receptor-binding protein SIVA. Apoptosis increased after cocultivating lymphocytes with the RCC cell lines A498 and CAKI2. The addition of recombinant soluble CD70 to both native lymphocytes and a T-cell cell line resulted in increased lymphocyte apoptosis as well. Furthermore, induced apoptosis could be partially blocked with anti-CD27 and anti-CD70 antibodies. Our results strongly indicate a role for CD70 and CD27 receptor in lymphocyte apoptosis within the tumor environment. Apoptosis mediated by exposure to the CD70 secreted by tumor cells may contribute to the failure of RCC patients to develop an effective lymphocyte-mediated antitumor response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132225      PMCID: PMC1716012          DOI: 10.1593/neo.06451

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  20 in total

1.  Where have all the T cells gone? Mechanisms of immune evasion by tumors.

Authors:  J Finke; S Ferrone; A Frey; A Mufson; A Ochoa
Journal:  Immunol Today       Date:  1999-04

2.  CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein.

Authors:  K V Prasad; Z Ao; Y Yoon; M X Wu; M Rizk; S Jacquot; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.

Authors:  R G Uzzo; P Rayman; V Kolenko; P E Clark; T Bloom; A M Ward; L Molto; C Tannenbaum; L J Worford; R Bukowski; R Tubbs; E D Hsi; N H Bander; A C Novick; J H Finke
Journal:  Clin Cancer Res       Date:  1999-05       Impact factor: 12.531

4.  Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma.

Authors:  Jörg Wischhusen; Gundram Jung; Ivan Radovanovic; Christoph Beier; Joachim P Steinbach; Andreas Rimner; Huatao Huang; Jörg B Schulz; Hiroko Ohgaki; Adriano Aguzzi; Hans-Georg Rammensee; Michael Weller
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

5.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Authors:  P Saas; P R Walker; M Hahne; A L Quiquerez; V Schnuriger; G Perrin; L French; E G Van Meir; N de Tribolet; J Tschopp; P Y Dietrich
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells.

Authors:  Gordon P Smyth; Philip P Stapleton; Catherine B Barden; Juan R Mestre; Tracy A Freeman; Michael D Duff; Sirish Maddali; Zhaoping Yan; John M Daly
Journal:  Ann Surg Oncol       Date:  2003-05       Impact factor: 5.344

7.  T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report.

Authors:  X Li; J Liu; J K Park; T A Hamilton; P Rayman; E Klein; M Edinger; R Tubbs; R Bukowski; J Finke
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

8.  Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor.

Authors:  R G Goodwin; M R Alderson; C A Smith; R J Armitage; T VandenBos; R Jerzy; T W Tough; M A Schoenborn; T Davis-Smith; K Hennen
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.

Authors:  J H Finke; P Rayman; L Hart; J P Alexander; M G Edinger; R R Tubbs; E Klein; L Tuason; R M Bukowski
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-02

10.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  28 in total

1.  CD70 expression patterns in renal cell carcinoma.

Authors:  Lucia B Jilaveanu; Joshua Sznol; Saadia A Aziz; Dylan Duchen; Harriet M Kluger; Robert L Camp
Journal:  Hum Pathol       Date:  2012-03-07       Impact factor: 3.466

2.  Gene expression profiling in MOLT-4 cells during gamma-radiation-induced apoptosis.

Authors:  Theres Lindgren; Torgny Stigbrand; Katrine Riklund; Lennart Johansson; David Eriksson
Journal:  Tumour Biol       Date:  2012-02-10

3.  CD70, a novel target of CAR T-cell therapy for gliomas.

Authors:  Linchun Jin; Haitao Ge; Yu Long; Changlin Yang; Yifan Emily Chang; Luyan Mu; Elias J Sayour; Gabriel De Leon; Qiong J Wang; James C Yang; Paul S Kubilis; Hongbo Bao; Songsong Xia; Dunyue Lu; Yingjun Kong; Li Hu; Yujiao Shang; Chencheng Jiang; Jing Nie; Shimin Li; Yunhe Gu; Jiahang Sun; Duane A Mitchell; Zhiguo Lin; Jianping Huang
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

4.  Decoy receptor 3 is a prognostic factor in renal cell cancer.

Authors:  Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

Review 5.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

6.  Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.

Authors:  M C Ryan; H Kostner; K A Gordon; S Duniho; M K Sutherland; C Yu; K M Kim; A Nesterova; M Anderson; J A McEarchern; C-L Law; L M Smith
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

7.  Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

Authors:  Qiong J Wang; Ken-Ichi Hanada; Paul F Robbins; Yong F Li; James C Yang
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

8.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

9.  Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.

Authors:  Jianhui Zhu; Song Nie; Jing Wu; David M Lubman
Journal:  J Proteome Res       Date:  2013-05-29       Impact factor: 4.466

Review 10.  Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Authors:  James H Finke; Pat A Rayman; Jennifer S Ko; Judy M Bradley; Sandra J Gendler; Peter A Cohen
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.